Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema

Ophthalmologica

Volumn 233, Issue , 2015, Pages 176-185

  Escobar Barranco, José Juan ^a   Pina Marín, Begoña ^a   Fernández Bonet, Manel ^a  

^a HOSPITAL DOS DE MAIG   (Spain)

Author keywords

Dexamethasone implant; Diabetic macular edema; Photocoagulation

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CATARACT; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG IMPLANT; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; RETINA HEMORRHAGE; SIDE EFFECT; VISUAL ACUITY; VITREOUS HEMORRHAGE; DIABETIC RETINOPATHY; DRUG EFFECTS; DRUG RESISTANCE; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PROSPECTIVE STUDY; RETINA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; DRUG RESISTANCE; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84930929141     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000371770     Document Type: Article

References (39)

1. Ciulla TA, Amador AG, Zinman B: Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-2664.
2. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP: Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-851.
3. Kocur I, Resnikoff S: Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002; 86: 716-722.
4. Al Dhibi HA, Arevalo JF: Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes 2013; 4: 295-302.
5. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806.
6. Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, Blasco-Sune C: Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev 2014; 10: 100-112.
7. Cheung N, Wong IY, Wong TY: Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care 2014; 37: 900-905.
8. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and Group RR: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
9. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N: Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46: 1440-1444.
10. Wang K, Wang Y, Gao L, Li X, Li M, Guo J: Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008; 31: 1541-1546.
11. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002; 80: 667-677.
12. Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C: Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother 2014; 15: 953-959.
13. Ozurdex-Summary of product characteristics (SPC). 2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001140/WC500095499.pdf (cited June 1, 2014).
14. FDA. Highlights of prescribing information Ozurdex. 2014. http://www. Accessdata.fda.gov/drugsatfda-docs/label/2014/022315s010lbl. pdf (cited December 2, 2014).
15. European Union's Committee for Medicinal Products for Human Use: Variation assessment report Ozurdex. 2014. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/001140/WC500173294.pdf (cited December 2, 2014).
16. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D: Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52: 80-86.
17. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM: Dexamethasone DDSPIISG. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: 289-296.
18. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM, Ozurdex CSG: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923.
19. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM, Ozurdex PSG: Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843-1851.
20. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MSG: Threeyear, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914.
21. Dong N, Xu B, Wang B, Chu L: Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis 2013; 19: 1734-1746.
22. Prasad S, Sung B, Aggarwal BB: Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev Med 2012; 54(suppl):S29-S37.
23. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B: Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2014; 231: 141-146.
24. Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, Turchetti P, Pacella F: Preliminary results of an intravitreal dexamethasone implant (Ozurdex ) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013; 7: 1423-1428.
25. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F: Repeated intravitreal dexamethasone implant (Ozurdex ) for retinal vein occlusion. Ophthalmologica 2013; 229: 21-25.
26. Zalewski D, Raczynska D, Raczynska K: Fivemonth observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant. Mediators Inflamm 2014; 2014: 364143.
27. Rishi P, Rishi E, Kuniyal L, Mathur G: Shortterm results of intravitreal dexamethasone implant (Ozurdex ) in treatment of recalcitrant diabetic macular edema: A case series. Oman J Ophthalmol 2012; 5: 79-82.
28. Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, Tomic Z: Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014; 34: 719-724.
29. Sharma A, Madhusudhan RJ, Nadahalli V, Damgude SA, Sundaramoorthy SK: Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report. Indian J Ophthalmol 2012; 60: 234-235.
30. Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, Bandello F: Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012; 228: 117-122.
31. Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, Prost-Magnin O, Meyer F: Multicenter Ozurdex assessment for diabetic macular edema: MOZART study (in French). J Fr Ophtalmol 2014; 37: 480-485.
32. Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J: Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci 2011; 52: 2741-2748.
33. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM, Kowalski JW: Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012; 119: 1190-1198.
34. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ, Ride; Group RR: Longterm outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.
35. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.e35.
36. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK; Diabetic Retinopathy Clinical Research Network: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
37. Grover D, Li TJ, Chong CC: Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008;CD005656.
38. Lambiase A, Abdolrahimzadeh S, Recupero SM: An update on intravitreal implants in use for eye disorders. Drugs Today (Barc) 2014; 50: 239-249.
39. Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, Parravano MC, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A: Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2014; 24: 1-9.